U.S. Markets close in 6 hrs 28 mins

Sientra, Inc. (SIEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.35-0.01 (-0.14%)
As of 9:31AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.36
Open7.34
Bid5.64 x 800
Ask7.80 x 800
Day's Range7.30 - 7.36
52 Week Range3.21 - 8.93
Volume28,203
Avg. Volume685,765
Market Cap422.777M
Beta (5Y Monthly)2.12
PE Ratio (TTM)N/A
EPS (TTM)-1.79
Earnings DateMay 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.71
  • Sientra Closes Sale of miraDry Business
    SmarterAnalyst

    Sientra Closes Sale of miraDry Business

    Sientra Inc. (SIEN) has closed the sale of its miraDry business. The medical aesthetics company has sold its subsidiary to 1315 Capital, a private investment firm. Following the news, shares of the company gained 2.2% to close at $7.60 in Friday’s extended trading session. Ron Menezes CEO of Sientra said, “We are delighted to close our transaction with 1315 Capital. With the sale of the miraDry business, we can now focus on our rapidly growing breast products business, and intend to utilize the

  • Sientra Announces Closing of Previously Announced Sale of miraDry Business to 1315 Capital
    GlobeNewswire

    Sientra Announces Closing of Previously Announced Sale of miraDry Business to 1315 Capital

    SANTA BARBARA, Calif., June 11, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced it has closed the previously announced sale of its miraDry business to 1315 Capital, a healthcare growth equity firm investing in commercial stage companies across medical devices, healthcare services, and therapeutics. The transaction was previously described in the Company’s Form 8-K filed on May 1

  • Sientra Announces Addition of Vice President of Research & Development
    GlobeNewswire

    Sientra Announces Addition of Vice President of Research & Development

    SANTA BARBARA, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra" or the “Company"), a medical aesthetics company uniquely focused on plastic surgeons, today announced the appointment of Denise Dajles as Vice President of Research & Development, effective today. In this new role, Ms. Dajles will report to Chief Executive Officer Ron Menezes and lead Sientra’s R&D and medical affairs teams. "We are pleased to welcome Denise to the Sientra management team," said Ron